Nestor Avgoustidis
YOU?
Author Swipe
View article: Long-term comparative analysis of secukinumab versus TNFα inhibitors in patients with spondyloarthritis: treatment persistence is differentially affected by disease phenotype, obesity and sex
Long-term comparative analysis of secukinumab versus TNFα inhibitors in patients with spondyloarthritis: treatment persistence is differentially affected by disease phenotype, obesity and sex Open
The differential persistence of biologic agents commonly used in SpA has been shown in this real-life prospective study. Should the distinct effects of obesity, sex and specific SpA diagnosis on persistence be confirmed in other cohorts, i…
View article: Combination of clinical factors predicts successful glucocorticoid withdrawal in systemic lupus erythematosus (SLE): results from a multicentre, retrospective cohort study
Combination of clinical factors predicts successful glucocorticoid withdrawal in systemic lupus erythematosus (SLE): results from a multicentre, retrospective cohort study Open
Objective Glucocorticoid (GC) tapering and withdrawal to reduce damage represents a key aspect of the European Alliance of Associations for Rheumatology (EULAR) SLE recommendations. However, optimal strategies for relapse-free GC cessation…
View article: P70 Exposure to DORIS ≥50% of time and to LLDAS ≥60% of observation time exhibit the best combination of feasibility and protection against adverse outcomes in moderate-to-severe SLE
P70 Exposure to DORIS ≥50% of time and to LLDAS ≥60% of observation time exhibit the best combination of feasibility and protection against adverse outcomes in moderate-to-severe SLE Open
Objective We assessed the attainment of remission (DORIS) and lupus low disease activity state (LLDAS) in patients with active moderate-to-severe disease and the minimum time dependent exposure associated to lower risk for organ damage acc…
View article: Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression
Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression Open
In moderate-to-severe SLE, sustained DORIS/LLDAS for at least 6 months is sufficient, while attainment for at least 24 months ensures higher specificity for damage-free progression, thus facilitating treat-to-target strategies and clinical…
View article: Patterns of comorbidities differentially affect long-term functional evolution and disease activity in patients with ‘difficult to treat’ rheumatoid arthritis
Patterns of comorbidities differentially affect long-term functional evolution and disease activity in patients with ‘difficult to treat’ rheumatoid arthritis Open
Background Characterisation of the long-term outcome of patients with ‘difficult to treat’ (D2T) rheumatoid arthritis and factors contributing to its evolution are unknown. Herein, we explored the heterogeneity and contributing factors of …
View article: A Peripheral Blood Signature of Increased Th1 and Myeloid Cells Combined with Serum Inflammatory Mediators Is Associated with Response to Abatacept in Rheumatoid Arthritis Patients
A Peripheral Blood Signature of Increased Th1 and Myeloid Cells Combined with Serum Inflammatory Mediators Is Associated with Response to Abatacept in Rheumatoid Arthritis Patients Open
Abatacept (CTLA4-Ig)—a monoclonal antibody which restricts T cell activation—is an effective treatment for rheumatoid arthritis (RA). Nevertheless, only 50% of RA patients attain clinical responses, while predictors of response are rather …
View article: Comorbidities Burden and Implementation of the Treat–to–Target Strategy in Predicting Real-World Patient Outcomes in Spondyloarthritides
Comorbidities Burden and Implementation of the Treat–to–Target Strategy in Predicting Real-World Patient Outcomes in Spondyloarthritides Open
New biologic and small molecule targeted agents have expanded the armamentarium of Spondyloarthritides (SpA), allowing more therapeutic options for patients who do not respond to therapy. The implementation of the treat-to-target (T2T) str…
View article: Progressive Multifocal Leukoencephalopathy in Systemic Lupus Erythematosus: A Consequence of Patient-Intrinsic or -Extrinsic Factors?
Progressive Multifocal Leukoencephalopathy in Systemic Lupus Erythematosus: A Consequence of Patient-Intrinsic or -Extrinsic Factors? Open
Progressive multifocal leukoencephalopathy (PML) is a severe demyelinating disease of the central nervous system (CNS) caused by reactivation of the polyomavirus JC (JCV) typically in immunocompromised individuals. The risk of PML among rh…
View article: Identification of Immune-Based Biomarkers Associated With Response to Abatacept (CTLA4-Ig) in Rheumatoid Arthritis Patients
Identification of Immune-Based Biomarkers Associated With Response to Abatacept (CTLA4-Ig) in Rheumatoid Arthritis Patients Open
Abatacept (CTLA4-Ig) – a monoclonal antibody which restricts T cell activation – is an effective treatment for rheumatoid arthritis (RA). Herein, we aimed to investigate for biomarkers of response to abatacept. We performed a d…
View article: Distinct long-term disease activity trajectories differentiate early on treatment with etanercept in both rheumatoid arthritis and spondylarthritis patients: a prospective cohort study
Distinct long-term disease activity trajectories differentiate early on treatment with etanercept in both rheumatoid arthritis and spondylarthritis patients: a prospective cohort study Open
To characterize disease activity trajectories and compare long-term drug retention between rheumatoid (RA) and spondylarthritis (SpA) patients initiating tumor necrosis factor inhibitor (TNFi) treatment (etanercept). Prospective observatio…
View article: Cost of Illness, Quality of Life, and Work Productivity in Axial Spondyloarthritis Patients Receiving Biological Treatments in Greece
Cost of Illness, Quality of Life, and Work Productivity in Axial Spondyloarthritis Patients Receiving Biological Treatments in Greece Open
The cost of illness in patients receiving biological treatments in Greece is high. However, these treatments except from the well-established positive effect on disease activity, can improve remarkably the work productivity and quality of …
View article: Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study
Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study Open
View article: Distinct Long-Term Disease Activity Trajectories Differentiate Early on Treatment with Etanercept in Both Rheumatoid Arthritis and Spondylarthritis Patients
Distinct Long-Term Disease Activity Trajectories Differentiate Early on Treatment with Etanercept in Both Rheumatoid Arthritis and Spondylarthritis Patients Open
View article: Bilateral Recurrent Uveitis in a Young Patient with Family History of Spondyloarthritis: Spondyloarthritis or Not?
Bilateral Recurrent Uveitis in a Young Patient with Family History of Spondyloarthritis: Spondyloarthritis or Not? Open
We present the case of a young man with a strong family history of SpA, who was referred to the Rheumatology Clinic due to bilateral uveitis refractory to treatment with corticosteroids. The patient's renal function gradually deteriorated …
View article: Tophaceous Pseudogout in the middle finger mimicking soft tissue tumor
Tophaceous Pseudogout in the middle finger mimicking soft tissue tumor Open
View article: Eosinophilic Fasciitis in a Patient With Crohn’s Disease Treated With Infliximab. A Rare Coexistence or a Drug-related Manifestation?
Eosinophilic Fasciitis in a Patient With Crohn’s Disease Treated With Infliximab. A Rare Coexistence or a Drug-related Manifestation? Open
View article: The value of the 2011 ASAS classification criteria in patients with Spondyloarthritis and the prognosis of non-radiographic axial Spondyloarthritis: data from a large cohort of a tertiary referral hospital
The value of the 2011 ASAS classification criteria in patients with Spondyloarthritis and the prognosis of non-radiographic axial Spondyloarthritis: data from a large cohort of a tertiary referral hospital Open
Spondyloarthritides (SpA) are a group of interrelated rheumatic disorders that includes ankylosing spondylitis (AS), psoriatic arthritis (PsA), arthritis related to inflammatory bowel disease and reactive arthritis. Since the latest classi…
View article: Nailfold Videocapillaroscopy as a Candidate Biomarker for Organ Involvement and Prognosis in Patients with Systemic Sclerosis
Nailfold Videocapillaroscopy as a Candidate Biomarker for Organ Involvement and Prognosis in Patients with Systemic Sclerosis Open
Background: Systemic Sclerosis (SSc) is a rare, multisystemic connective tissue disease associated with significant morbidity. Early recognition of patients at risk for adverse prognosis may help towards optimized monitoring and treatment,…
View article: Comparative analysis of the sensitivity and specificity of the classification criteria and correlation with prognosis of disease in patients with Systemic Lupus Erythematosus
Comparative analysis of the sensitivity and specificity of the classification criteria and correlation with prognosis of disease in patients with Systemic Lupus Erythematosus Open
This is the first study to include the application of the new criteria (EULAR/ACR 2018) to a group of SLE patients. Determining their diagnostic value in comparison to existing criteria or diagnosis by a specialist will provide important i…
View article: Canakinumab for recurrent rheumatic disease associated-pericarditis: a case series with long-term follow-up
Canakinumab for recurrent rheumatic disease associated-pericarditis: a case series with long-term follow-up Open
View article: P016 Baseline levels of IL-17-producing CD4+ T cells predict clinical response to abatacept in rheumatoid arthritis patients
P016 Baseline levels of IL-17-producing CD4+ T cells predict clinical response to abatacept in rheumatoid arthritis patients Open
View article: SAT0204 Abatacept survival in rheumatoid arthritis patients at 2 years is 59%; its use as a 2nd line biologic agent and lower baseline haq predict better survival in clinical practice: a prospective, observational single center study
SAT0204 Abatacept survival in rheumatoid arthritis patients at 2 years is 59%; its use as a 2nd line biologic agent and lower baseline haq predict better survival in clinical practice: a prospective, observational single center study Open
View article: FRI0236 After discontinuation of the 1st tumor necrosis factor inhibitor (TNFI), non-tnfi biologic agents have similar responses but higher survival compared to a 2nd course of a different tnfi: long-term prospective observational study of patients with rheumatoid arthritis in a tertiary hospital of greece
FRI0236 After discontinuation of the 1st tumor necrosis factor inhibitor (TNFI), non-tnfi biologic agents have similar responses but higher survival compared to a 2nd course of a different tnfi: long-term prospective observational study of patients with rheumatoid arthritis in a tertiary hospital of greece Open
View article: FRI0244 Low dose of rituximab is effective for maintenance of clinical remission or low disease activity in patients with rheumatoid arthritis
FRI0244 Low dose of rituximab is effective for maintenance of clinical remission or low disease activity in patients with rheumatoid arthritis Open
View article: SAT0330 Lower prevalence but comparable clinical characteristics and prognosis of systemic sclerosis in crete-greece as compared to other european countries: a single center experience
SAT0330 Lower prevalence but comparable clinical characteristics and prognosis of systemic sclerosis in crete-greece as compared to other european countries: a single center experience Open
View article: Immunoprofiling for Prediction of Response to Abatacept in Rheumatoid Arthritis Patients
Immunoprofiling for Prediction of Response to Abatacept in Rheumatoid Arthritis Patients Open
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease which causes musculoskeletal pain, disability and reduced life expectancy. Activation of immune cells – especially - T helper (Th) lymphocytes - resulting in aberrant p…